
    
      This is a Phase 2, multicenter, randomized, double-blind, double-dummy, active-controlled,
      dose-ranging study of female subjects with moderate to severe Acute Vulvovaginal Candidiasis.
      Subjects will be randomized to either the investigational arm (SCY-078) with 5 different dose
      regiments ranging from 1 to 3 days of treatment or to the active-control arm (fluconazole)
      for 1 day of treatment. After randomization subjects may be seen on study Day 3 (on site
      visit for PK subjects) , Day 10 (Â±2,) and Day 25 (+4).
    
  